Anti-Parkinson Drugs Market Report 2026

Anti-Parkinson Drugs Market Overview

• Anti-Parkinson Drugs market size has reached to $10.96 billion in 2025 • Expected to grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Increasing Incidence Of Mental Health Disorders Driving Market Growth Due To Rising Need For Supportive Wellness Solutions • Market Trend: Innovative Advancements In The Anti-Parkinson Drugs Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Anti-Parkinson Drugs Market?

Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson's disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic's negative effects. The main class of anti-Parkinson drugs is levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type b (MAO-b) inhibitors, catechol-o-methyltransferase (COMT)-inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors are a class of drugs used to treat Parkinson's disease symptoms in conjunction with carbidopa-levodopa therapy. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered through oral, injection, and transdermal that are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Anti-Parkinson Drugs Market Growth Forecast?

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $14.28 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising neurodegenerative disorders, innovation in neuroprotective drugs, expansion of transdermal therapies, increased healthcare access, focus on quality of life improvement. Major trends in the forecast period include rising demand for dopaminergic therapies, growing use of extended-release formulations, increasing focus on symptom management, expansion of combination drug therapies, improved drug delivery technologies.

Global Anti-Parkinson Drugs Market Segmentation

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs 2) By Route of Administration: Oral, Injection, Transdermal 3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies Subsegments: 1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa 2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine 3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide 4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone 5) By Anticholinergics: Benztropine, Trihexyphenidyl 6) By Other Drugs: Amantadine, Apomorphine

What Is The Driver Of The Anti-Parkinson Drugs Market?

The increasing incidence of mental health disorders is expected to propel the growth of the mental wellness market going forward. The mental health disorders is a clinically substantial impairment in a person's cognition, emotional regulation, or conduct. The rising prevalence of mental disorders is due to increasing exposure to chronic stress and adverse life experiences that overwhelm individual coping mechanisms and trigger psychological dysfunction. The increasing incidence of mental disorders expands the anti-Parkinson drugs market as it aids in minimizing mental disorders and cures them. For instance, in October 2025, according to the Institute for Health Metrics and Evaluation, a US-based health research organization, 15% of the world’s population experienced mental disorders in 2023 and 17% of the total years lived with disability globally were attributed to mental disorders in the same year. Therefore, the high prevalence of mental disorder is driving the growth of the anti-Parkinson drugs industry.

Key Players In The Global Anti-Parkinson Drugs Market

Major companies operating in the anti-parkinson drugs market are GlaxoSmithKline plc, Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Global Anti-Parkinson Drugs Market Trends and Insights

Major companies operating in the anti-Parkinson drugs market are focused on developing advanced therapeutic solutions such as motor fluctuations and dyskinesia to enhance symptom control and minimize side effects. Motor fluctuations and dyskinesia often complicate the treatment of Parkinson's disease, affecting patient well-being. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa) is the first subcutaneous 24-hour infusion therapy for advanced Parkinson's disease, specifically addressing severe motor fluctuations and dyskinesia when other treatments fail. It continuously delivers levodopa, potentially increasing 'on' time and improving symptom control.

What Are Latest Mergers And Acquisitions In The Anti-Parkinson Drugs Market?

In October 2023, AbbVie Inc., a US-based pharmaceutical company, acquired Mitokinin for $110 million. With this acquisition, AbbVie Inc. aims to strengthen the neuroscience pipeline and provide a new treatment option for Parkinson patients. Mitokinin is a US-based biotechnology company that provides treatments for Parkinson disease (PD).

Regional Insights

North America was the largest region in the anti-Parkinson drugs market in 2025. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-Parkinson Drugs Market?

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Parkinson Drugs Market Report 2026?

The anti-parkinson drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-parkinson drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.